Clinical pharmacists participated in the treatment of a case of diabetic ketoacidosis with urinary tract infection and bloodstreanm infection, which was later caused by Clostridium difficile-related diarrhea due to long-term use of antibacterial drugs. According to the patient's condition and pathogenic test results, clinical pharmacists consulted domestic and foreign guidelines through daily pharmaceutical rounds and consultations. After discussing with clinicans, considered that the patient had catheter-related carbapenem-resistant Klebsiella pneumoniae bloodstream infection. It was suggested to remove the femoral vein catheter and use tigecycline 100 mg, q12h combined with imipenem cilastatin 1 g, q8h for anti-infection treatment at the same time. In the later consultation, the patient was advised to take vancomycin 125 mg, q6h orally for the diarrhea of Clostridium difficile associated with antibiotics by physicians and clinicans adopted the opinions. The patient recovered without other adverse drug reactions, and discharged finally. Clinical pharmacists played an active and effective role in the practice of anti-infective pharmacology, which fully embodied the professional value in multidisciplinary collaborative diagnosis and treatment.

1.Umpierrez G, Korytkowski M. Diabetic emergencies-ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia[J]. Nat Rev Endocrinol, 2016, 12(4): 222-232. DOI: 10.1038/nrendo.2016.15.

2.Dhatariya KK, Glaser NS, Codner E, et al. Diabetic ketoacidosis[J]. Nat Rev Dis Primers, 2020, 6(1): 40. DOI: 10.1038/s41572-020-0165-1.

3.Randall L, Begovic J, Hudson M, et al. Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors[J]. Diabetes Care, 2011, 34(9): 1891-1896. DOI: 10.2337/dc11-0701.

4.胡付品, 郭燕, 朱德妹,等. 2021年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2022, 22(5): 521-530. [Hu FP, Guo Y, Zhu DM, et al. CHINET surveillance of antimicrobial resistance among the bacterial isolates in 2021[J]. Chinese Journal of Infection and Chemotherapy, 2022, 22(5): 521-530.] DOI: 10.16718/j.1009-7708.2022. 05.001.

5.中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)(上)[J].中国实用内科杂志, 2021, 41(8): 668-695. DOI: 10.19538/j.nk2021080106.

6.Dhatariya KK, Umpierrez GE. Guidelines for management of diabetic ketoacidosis: time to revise?[J]. Lancet Diabetes Endocrinol, 2017, 5(5): 321-323. DOI: 10.1016/S2213-8587(17)30093-1.

7.Glaser N, Fritsch M, Priyambada L, et al. ISPAD clinical practice consensus guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state[J]. Pediatr Diabetes, 2022, 23(7): 835-856. DOI: 10.1111/pedi.13406.

8.陈锡得. 降钙素原与血常规联合检测在糖尿病酮症酸中毒合并感染患者诊治中的应用[D]. 福州: 福建医科大学, 2016.

9.Randall L, Begovic J, Hudson M, et al. Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors[J]. Diabetes Care, 2011, 34(9): 1891-1896. DOI: 10.2337/dc11-0701.

10.何小霞, 王旭, 陈中举. 社区获得性细菌尿路感染病原学分析[J]. 医药导报, 2020, 39(5): 695-698. [He XX, Wang X, Chen ZJ. Etiological analysis of community acquired bacterial urinary tract infections[J]. Herald of Medicine, 2020, 39(5): 695-698.] DOI: 10.3870/j.issn. 1004-0781.2020.05.025.

11.Qiao LD, Chen S, Yang Y, et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study[J]. BMJ Open, 2013, 3(12): e004152. DOI: 10.1136/bmjopen-2013-004152.

12.Kamei J, Yamamoto S. Complicated urinary tract infections with diabetes mellitus[J]. J Infect Chemother, 2021, 27(8): 1131-1136. DOI: 10.1016/j.jiac.2021.05.012.

13.中国女医师协会肾脏病与血液净化专委会. 中国女性尿路感染诊疗专家共识[J]. 中华医学杂志, 2017, 97(36): 2827-2832. DOI: 10.3760/cma.j.issn.0376-2491. 2017.36.010.

14.Ternes B, Wagenlehner FME. Leitliniengerechte therapie von harnwegsinfektionen [Guideline-based treatment of urinary tract infections][J]. Urologe A, 2020, 59(5): 550-558. DOI: 10.1007/s00120-020-01174-0.

15.中华医学会呼吸病学分会感染学组. 中国铜绿假单胞菌下呼吸道感染诊治专家共识(2022年版)[J]. 中华结核和呼吸杂志, 2022, 45(8): 739-752. DOI: 10.3760/cma.j.cn112147-20220407-00290.

16.Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America[J]. Clin Infect Dis, 2016, 62(4): e1-50. DOI: 10.1093/cid/civ933.

17.Chen J, Ma H, Huang X, et al. Risk factors and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary-care hospital in China: an eight-year retrospective study[J]. Antimicrob Resist Infect Control, 2022, 11(1): 161. DOI: 10.1186/s13756-022-01204-w.

18.中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识编写组, 中国医药教育协会感染疾病专业委员会, 中华医学会细菌感染与耐药防控专业委员会. 中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识[J]. 中华医学杂志, 2021, 101(36): 2850-2860. DOI: 10.3760/cma.j.cn112137-20210219-00438.

19.Falagas ME, Kyriakidou M, Voulgaris GL, et al. Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: an evaluation of the current evidence[J]. J Glob Antimicrob Resist, 2021, 24: 342-359. DOI: 10.1016/j.jgar.2020.12.026.

20.Karaiskos I, Daikos GL, Gkoufa A, et al. Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study[J]. J Antimicrob Chemother, 2021, 76(3): 775-783. DOI: 10.1093/jac/dkaa503.

21.Pascale R, Giannella M, Bartoletti M, et al. Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections[J]. Expert Rev Anti Infect Ther, 2019, 17(10): 819-827. DOI: 10.1080/14787210. 2019.1673731.

22.中国医药教育协会感染疾病专业委员会. 抗菌药物药代动力学/药效学理论临床应用专家共识[J]. 中华结核和呼吸杂志, 2018, 41(6): 409-446. DOI: 10.3760/cma.j.issn.1001-0939.2018.06.004.

23.Zha L, Pan L, Guo J, et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis[J]. Adv Ther, 2020, 37(3): 1049-1064. DOI: 10.1007/s12325-020-01235-y.

24.Xia G, Jiang R. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: a retrospective analysis[J]. Medicine (Baltimore), 2020, 99(10): e19466. DOI: 10.1097/MD.0000000000019466.

25.Dionne JC, Mbuagbaw L, Devlin JW, et al. Diarrhea during critical illness: a multicenter cohort study[J]. Intensive Care Med, 2022, 48(5): 570-579. DOI: 10.1007/s00134-022-06663-8.

26.朱佳源, 谭周进, 郑淘, 等. 艰难梭菌与抗生素相关腹泻的研究进展[J]. 中国感染控制杂志, 2021, 20(12): 1168-1173. [Zhu JY, Tan ZJ, Zheng T, et al. Advances in clostridium difficile and antibiotic-associated diarrhea[J]. Chinese Journal of Infection Control, 2021, 20(12): 1168-1173.] DOI: 10.12138/j.issn.1671-9638.20218037.

27.中国医师协会检验医师分会感染性疾病检验医学专家委员会. 中国成人艰难梭菌感染诊断和治疗专家共识[J]. 协和医学杂志, 2017, 8(Z1): 131-138. DOI: 10.3969/j.issn.1674-9081.2017.03.010.

28.戴维·吉尔伯特, 主编. 范洪伟, 主译. 桑福德抗微生物治疗指南, 第50版[M]. 北京: 中国协和医科大学出版社, 2021: 20.

29.Wu KS, Syue LS, Cheng A, et al. Recommendations and guidelines for the treatment of Clostridioides difficile infection in Taiwan[J]. J Microbiol Immunol Infect, 2020, 53(2): 191-208. DOI: 10.1016/j.jmii.2020.02.002.

30.Oksi J, Anttila VJ, Mattila E. Treatment of Clostridioides (Clostridium) difficile infection[J]. Ann Med, 2020, 52(1-2): 12-20. DOI: 10.1080/07853890.2019.1701703.

31.王荧, 乔逸, 杨志福, 等.替加环素致不良反应文献分析[J]. 中国药物应用与监测, 2022, 19(2): 109-112. [Wang Y, Qiao Y, Yang ZF, et al. Literature analysis of adverse reaction induced by tigecycline[J]. Chinese Journal of Drug Application and Monitoring, 2022, 19(2): 109-112.] DOI: 10.3969/j.issn.1672-8157.2022.02.012.